

Marianne Patt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11223326/publications.pdf>

Version: 2024-02-01

70
papers

2,282
citations

218677

26
h-index

243625

44
g-index

77
all docs

77
docs citations

77
times ranked

2999
citing authors

#	ARTICLE	IF	CITATIONS
1	EANM position on the in-house preparation of radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1095-1098.	6.4	12
2	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	12.8	34
3	Multicenter ¹⁸ F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease. <i>Biomolecules</i> , 2022, 12, 458.	4.0	9
4	PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 33S-44S.	5.0	21
5	Molecular Simulations Reveal Distinct Energetic and Kinetic Binding Properties of [¹⁸ F]PI-2620 on Tau Filaments from 3R/4R and 4R Tauopathies. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2222-2234.	3.5	10
6	(+)-[¹⁸ F]Flubatine as a novel $\alpha 4\beta 2$ nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with $\beta 2$ -amyloid PET-confirmed Alzheimer's disease and healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 731-746.	6.4	10
7	Emerging Radionuclides in a Regulatory Framework for Medicinal Products—How Do They Fit?. <i>Frontiers in Medicine</i> , 2021, 8, 678452.	2.6	12
8	Cortical [¹⁸ F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. <i>Movement Disorders</i> , 2021, 36, 2104-2115.	3.9	46
9	Binding characteristics of [¹⁸ F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2957-2972.	4.3	30
10	Feasibility of short imaging protocols for [¹⁸ F]PI-2620 tau-PET in progressive supranuclear palsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3872-3885.	6.4	22
11	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [¹⁸ F]PI-2620. <i>Frontiers in Neurology</i> , 2021, 12, 684523.	2.4	11
12	Feasibility of short imaging protocols for [¹⁸ F]PI-2620 tau-PET in progressive supranuclear palsy. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
13	Assessment of ¹⁸ F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2020, 77, 1408.	9.0	145
14	Higher HbA1c levels associate with lower hippocampal serotonin transporter availability in non-diabetic adults with obesity. <i>Scientific Reports</i> , 2020, 10, 21383.	3.3	0
15	¹⁸ F-PI-2620 tau-PET in corticobasal syndrome (ActiGliA cohort). <i>Alzheimer's and Dementia</i> , 2020, 16, e041469.	0.8	1
16	Quantitative susceptibility mapping in $\beta 2$ -Amyloid PET-stratified patients with dementia and healthy controls—A hybrid PET/MRI study. <i>European Journal of Radiology</i> , 2020, 131, 109243.	2.6	10
17	Early-phase [¹⁸ F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2911-2922.	6.4	36
18	Current radiotracers to image neurodegenerative diseases. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 17.	3.9	28

#	ARTICLE	IF	CITATIONS
19	In vitro and in vivo Human Metabolism of (S)-[18F]Fluspidine – A Radioligand for Imaging β 1 Receptors With Positron Emission Tomography (PET). <i>Frontiers in Pharmacology</i> , 2019, 10, 534.	3.5	9
20	Radionuclides: medicinal products or rather starting materials?. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 22.	3.9	11
21	Early after Administration [11C]PiB PET Images Correlate with Cognitive Dysfunction Measured by the CERAD Test Battery. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 65-76.	2.6	4
22	Central noradrenaline transporter availability is linked with HPA axis responsiveness and copeptin in human obesity and non-obese controls. <i>Stress</i> , 2019, 22, 93-102.	1.8	9
23	IC ₅₀ : 18F-Pi2620 TAU-PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTI-CENTER EVALUATION. <i>Alzheimer's and Dementia</i> , 2019, 15, P128.	0.8	3
24	Noradrenaline transporter availability on [11C]MRB PET predicts weight loss success in highly obese adults. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1618-1625.	6.4	7
25	Cognitive correlates of α 2 nicotinic acetylcholine receptors in mild Alzheimer's dementia. <i>Brain</i> , 2018, 141, 1840-1854.	7.6	60
26	Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1105-1116.	2.6	20
27	Exploring the Metabolism of (+)-[18F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided Identification of Radiometabolites in a Clinical PET Study –. <i>Molecules</i> , 2018, 23, 464.	3.8	9
28	Quantitative Susceptibility Mapping of Amyloid- β Aggregates in Alzheimer's Disease with 7T MR. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 393-404.	2.6	39
29	Evaluation of early-phase [18 F]-florbetaben PET acquisition in clinical routine cases. <i>NeuroImage: Clinical</i> , 2017, 14, 77-86.	2.7	91
30	Dissociation Between Brown Adipose Tissue ¹⁸ F-FDG Uptake and Thermogenesis in Uncoupling Protein 1-Deficient Mice. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1100-1103.	5.0	73
31	Central noradrenaline transporter availability in highly obese, non-depressed individuals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1056-1064.	6.4	50
32	Test-retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1025-1032.	6.4	50
33	Gastric Bypass Surgery Recruits a Gut PPAR- α -Striatal D1R Pathway to Reduce Fat Appetite in Obese Rats. <i>Cell Metabolism</i> , 2017, 25, 335-344.	16.2	108
34	Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2239-2248.	6.4	15
35	The association between in vivo central noradrenaline transporter availability and trait impulsivity. <i>Psychiatry Research - Neuroimaging</i> , 2017, 267, 9-14.	1.8	11
36	European regulations for the introduction of novel radiopharmaceuticals in the clinical setting. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 135-144.	0.7	33

#	ARTICLE	IF	CITATIONS
37	Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [¹¹ C] DASB positron emission tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1096-1104.	6.4	22
38	Early [¹⁸ F]florbetaben and [¹¹ C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1700-1709.	6.4	69
39	Effortful control as a dimension of temperament is negatively associated with prefrontal serotonin transporter availability in obese and non-obese individuals. <i>European Journal of Neuroscience</i> , 2016, 44, 2460-2466.	2.6	6
40	Feasibility and acceptance of simultaneous amyloid PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2236-2243.	6.4	25
41	Radiation dosimetry of the ¹²⁵ I nicotinic receptor ligand (+)-[¹⁸ F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results. <i>EJNMMI Physics</i> , 2016, 3, 25.	2.7	17
42	Fully automated calculation of image-derived input function in simultaneous PET/MRI in a sheep model. <i>EJNMMI Physics</i> , 2016, 3, 2.	2.7	20
43	In-vivo serotonin transporter availability and somatization in healthy subjects. <i>Personality and Individual Differences</i> , 2016, 94, 354-359.	2.9	3
44	Partial-Volume Effect Correction Improves Quantitative Analysis of ¹⁸ F-Florbetaben ¹²⁵ I-Amyloid PET Scans. <i>Journal of Nuclear Medicine</i> , 2016, 57, 198-203.	5.0	58
45	Suppressed Fat Appetite after Roux-en-Y Gastric Bypass Surgery Associates with Reduced Brain ¹²⁵ I-opioid Receptor Availability in Diet-Induced Obese Male Rats. <i>Frontiers in Neuroscience</i> , 2016, 10, 620.	2.8	15
46	A Promising PET Tracer for Imaging of ¹²⁵ I Nicotinic Acetylcholine Receptors in the Brain: Design, Synthesis, and in Vivo Evaluation of a Dibenzo-thiophene-Based Radioligand. <i>Molecules</i> , 2015, 20, 18387-18421.	3.8	13
47	Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 539-543.	2.6	7
48	Simultaneous PET/Mri in Stroke: A Case Series. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1421-1425.	4.3	57
49	First-in-human PET quantification study of cerebral ¹²⁵ I nicotinic acetylcholine receptors using the novel specific radioligand (S)-[¹⁸ F]Flubatine. <i>NeuroImage</i> , 2015, 118, 199-208.	4.2	49
50	Ethnic comparison of pharmacokinetics of ¹⁸ F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 89-96.	6.4	8
51	Internal Dose Assessment of (S)- ¹⁸ F-Flubatine, Comparing Animal Model Datasets of Mice and Piglets with First-in-Human Results. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1885-1892.	5.0	17
52	Distinctive In Vivo Kinetics of the New ¹²⁵ I Receptor Ligands (R)- and (S)-(¹⁸ F)- ¹⁸ F-Fluspidine in Porcine Brain. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1730-1736.	5.0	26
53	Altered serotonin transporter availability in patients with multiple sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 827-835.	6.4	56
54	Synthesis and biological evaluation of both enantiomers of [¹⁸ F]flubatine, promising radiotracers with fast kinetics for the imaging of ¹²⁵ I-nicotinic acetylcholine receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 804-812.	3.0	29

#	ARTICLE	IF	CITATIONS
55	Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (α)-[18F]Flubatine in humans. <i>Nuclear Medicine and Biology</i> , 2014, 41, 489-494.	0.6	18
56	Fully automated radiosynthesis of both enantiomers of [18F]Flubatine under GMP conditions for human application. <i>Applied Radiation and Isotopes</i> , 2013, 80, 7-11.	1.5	20
57	PET Quantification of 18 F-Florbetaben Binding to β -Amyloid Deposits in Human Brains. <i>Journal of Nuclear Medicine</i> , 2013, 54, 723-731.	5.0	101
58	Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1001-1011.	6.4	30
59	Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter. <i>Journal of Neurology</i> , 2011, 258, 19-26.	3.6	65
60	Decreased cerebral α 7 nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 515-525.	6.4	109
61	Individualized quantification of brain β -amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1702-1714.	6.4	91
62	The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 606-617.	2.1	53
63	Reduced α 7 Nicotinic Acetylcholine Receptor Binding and Its Relationship to Mild Cognitive and Depressive Symptoms in Parkinson Disease. <i>Archives of General Psychiatry</i> , 2009, 66, 866.	12.3	140
64	In vivo measurement of nicotinic acetylcholine receptors with [18 F]norchloroethanehomoepibatidine. <i>Synapse</i> , 2008, 62, 205-218.	1.2	47
65	Measurement of the α 7 nicotinic acetylcholine receptor ligand 2-[18F]Fluoro-A-85380 and its metabolites in human blood during PET investigation: a methodological study. <i>Nuclear Medicine and Biology</i> , 2007, 34, 331-342.	0.6	22
66	Synthesis procedure for routine production of 2-[18F]fluoro-3-(2(S)-azetidylmethoxy)pyridine (2-[18F]F-A-85380). <i>Applied Radiation and Isotopes</i> , 2007, 65, 1244-1248.	1.5	16
67	Synthetic approaches and bio-distribution studies of [11C]methyl-phenidate. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2007, 10, 312s-320s.	2.1	1
68	Binding properties of the cerebral α 7 nicotinic acetylcholine receptor ligand 2-[18F]fluoro-A-85380 to plasma proteins. <i>Nuclear Medicine and Biology</i> , 2006, 33, 899-906.	0.6	12
69	Autoradiography of 2-[18F]F-A-85380 on nicotinic acetylcholine receptors in the porcine brain in vitro. <i>Synapse</i> , 2006, 59, 201-210.	1.2	11
70	Nicotinic acetylcholine receptors in patients with Parkinson's disease and Alzheimer's disease: Specific binding of 2-[18F]F-A-85380 in the cerebral white matter as demonstrated by PET and comparison with diffusion tensor MRI (DTI). <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S584-S584.	4.3	0